[MO29] Mini-Oral Session 29　Lung Cancer / Thoracic Cancer 4（EGFR-TKI 1）
【E】

[MO29-4] Sequential afatinib and osimertinib in Asians with EGFRm+ NSCLC: combined analysis of two non-interventional studies

^○Satoru Miura¹, Hyun Ae Jung², Shin Yup Lee³, Seung Hyeun Lee⁴, Min Ki Lee⁵, Yong Chul Lee⁶, Maximilian J Hochmair⁷, Cheng-Ta Yang⁸, Angela Märten⁹, James Chih-Hsin Yang¹⁰, Sanjay Popat^11,12 (1.Department of Internal Medicine, Niigata Cancer Center Hospital, 2.Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 3.Department of Internal Medicine, School of Medicine, Kyungpook National University, Daegu, South Korea, 4.Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, Kyung Hee University Medical Center, Kyung Hee University School of Medicine, Seoul, South Korea, 5.Department of Internal Medicine, Pusan National University School of Medicine, Busan, South Korea, 6.Department of Internal Medicine, Research Institute of Clinical Medicine of Chonbuk National University, Biomedical Research Institute of Chonbuk National University Hospital, Chonbuk National Univers, 7.Department of Respiratory & Critical Care Medicine, Karl Landsteiner Institute of Lung Research & Pulmonary Oncology, Vienna, Austria, 8.Department of Thoracic Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan, 9.Boehringer Ingelheim International GmbH, Ingelheim am Rhein, Germany, 10.Department of Medical Oncology, National Taiwan University Cancer Center and Department of Oncology, National Taiwan University Hospital, Taipei, Taiwan, 11.Lung Unit, Royal Marsden National Health Service Foundation Trust, London, United Kingdom, 12.The Institute of Cancer Research, London, United Kingdom)